CD326 (EpCAM) Flow Cytometry: Domain Architecture, Wnt Signaling and Circulating Tumor Cell Capture
An Adhesion Molecule That Fits No Family
Cell-surface adhesion molecules are usually sorted into four subfamilies: integrins, selectins, cadherins and the immunoglobulin superfamily. EpCAM belongs to none of them. The molecule was first described in 1979 as a major tumor-associated antigen in human colon cancer tissue. In 2006, the first international symposium on EpCAM biology and clinical application, held in the Netherlands, unified the name as EpCAM and assigned the CD designation CD326.
Gene, Exons and Domain Layout
| Parameter | Detail |
|---|---|
| Encoding gene | GA733-2, chromosome 4q; TACSTD1 also reported |
| Gene span | minimum 14 kb |
| Mature mRNA | approximately 1.5 kb |
| Open reading frame | 942 bp |
| Exon structure | nine exons: exon 1, 5' UTR signal sequence; exons 2–6, extracellular region; exon 7, transmembrane region; exons 8–9, intracellular region and 3' UTR |
| Protein class | calcium-independent type I transmembrane glycoprotein, 33–40 kDa |
| Domains | EpEX carrying EGF-like and thyroglobulin-like repeats; 23 hydrophobic transmembrane residues; 26-residue intracellular domain |
| Motifs | NPXY internalization motif and two α-actinin binding sites |
| Glycosylation | cysteine-rich N-terminus, three potential N-glycosylation sites, giving 38, 40 and 42 kDa forms |
The extracellular portion carries an EGF-like repeat and a thyroglobulin-like repeat. These repeats form the structural basis for homotypic adhesion. On the cell surface, EpCAM exists as multimers. The EGF-like domain initiates contact between neighbouring molecules. The TY domain then draws two opposing cells closer, and the molecules twist into a tetramer at that interface.
Regulated Intramembrane Proteolysis Feeds the Wnt Pathway
EpCAM promotes proliferation and adhesion, and it modulates differentiation. It also transmits signals from cytoplasm to nucleus. Overexpression of EpCAM or its domains accelerates proliferation in vitro and in vivo, while knockdown slows it.
Activation proceeds through regulated intramembrane proteolysis. Tumor necrosis factor-α converting enzyme and the γ-secretase complex cleave the molecule, releasing EpEX and the intracellular domain EpICD. Inside the cell, EpICD assembles with β-catenin, Lef and FHL2 into a nuclear complex of roughly 650 kDa. FHL2 is the cytoplasmic partner. Its LIM domain 4 is required for EpCAM binding, while LIM domains 2 and 3 engage β-catenin and p300.
The complex then enters the nucleus and binds the transcription factor Lef. Three target genes follow: CD44, Cyclin D1 and c-Myc. Upregulated c-Myc reinforces Wnt signaling, and upregulated cyclins drive proliferation. A second axis runs in parallel. High EpCAM lowers PTEN and E-cadherin, and it raises P-AKT, P-mTOR, P-P70s6K and P-4EBP1, activating PI3K/Akt/mTOR. Through PI3 kinase, EpCAM can also interfere with E-cadherin-dependent adhesion.
Why Epithelium-Only Expression Makes a CTC Marker
CD326 participates in tumor microenvironment regulation. It mediates contacts between tumor cells and stromal components, and it contributes to migration, differentiation and signal transduction. In clinical research, expression across epithelial-derived malignancies makes it a candidate diagnostic and therapeutic target.
The most established use is positive selection. Epithelial tumor cells are enriched from peripheral blood, bone marrow, lymphocytes and serous cavity effusions. The logic is anatomical. EpCAM is expressed on epithelial cells, and those cells are normally absent from blood, marrow and lymphoid tissue. An EpCAM-positive event in those compartments therefore suggests a disseminated epithelial tumor cell. This is why EpCAM became the most common capture marker for circulating tumor cells. In some tumor types, high CD326 also tracks with advanced stage and shorter overall survival.
Five Readouts Built on One Marker
| Workflow | Gating logic | Companion markers |
|---|---|---|
| CTC enumeration | EpCAM-positive, CD45-negative events | CD45 |
| Cell line authentication | retained epithelial phenotype | none required |
| Cancer stem cell sorting | EpCAM-high fraction | CD44, CD24 |
| Phenotype heterogeneity | multicolor subsetting of epithelial cells | CD44, CD24 |
| Therapy response | shift in surface EpCAM density | target-specific panel |
From Capture to Confirmation
Capture and confirmation are separate claims. Enrichment on EpCAM recovers epithelial cells, but recovery depends on antigen density, and density falls during epithelial-to-mesenchymal transition. Confirmation therefore uses an orthogonal marker set rather than EpCAM alone. A typical panel combines a leukocyte marker to exclude hematopoietic events, a viability dye to exclude dead cells, and a cytokeratin stain to establish epithelial identity. Each additional marker lowers the recovered count and raises confidence in the remaining ones. Report both numbers. A study that quotes only purity hides the recovery cost, and a study that quotes only recovery hides the false-positive rate.
Choosing Clone and Fluorophore
Species comes first. The human reagent uses clone S-R464, available with FITC or PerCP-Cy5.5. The mouse reagent uses clone S-R627, available unconjugated or with FITC. A rat anti-mouse clone will not read human cells, whatever the fluorophore.
Format comes second. FITC suits compact panels and bright targets. PerCP-Cy5.5 places the signal in a detector that pairs well with FITC and PE, but tandem dyes of this class are sensitive to fixation and prolonged light exposure. Unconjugated formats remain useful when the panel has no free channel, or when a secondary step is needed for signal amplification.
Biology comes third, and it is where most errors originate. EpCAM is also present on normal epithelium, including gut, liver and breast. It can be downregulated during epithelial-to-mesenchymal transition. Sample type, dissociation and clone should therefore be validated together rather than assumed.
Two Models of the Adhesion Interface
Two schematic models of EpCAM trans-interaction at the plasma membrane, the Litvinov model and an alternative model
The figure contrasts two depictions of the same interface. In the Litvinov model, EGF-like domain I and domain II of opposing molecules engage directly. In the alternative model, the TY domain forms the primary contact and the EGF-like domains sit to the side, with a possible cathepsin-sensitive step indicated.
Neither model changes a gating strategy. Both explain why epitope accessibility depends on oligomeric state. A clone raised against the EGF-like region may behave differently on a monomer than on a tetramer. When staining looks unexpectedly weak on a cell type that should express EpCAM, the assembly state is worth considering before the antibody is blamed.
Product Information
| Cat. No. | Product Name | Host and Clone | Conjugate | Species | Purchase |
|---|---|---|---|---|---|
| S0B1681 | FITC Mouse Anti-Human CD326 (EpCAM) Antibody (S-R464) | Mouse, S-R464 | FITC | Human | |
| S0B1810 | PerCP-Cy5.5 Mouse Anti-Human CD326 (EpCAM) Antibody (S-R464) | Mouse, S-R464 | PerCP-Cy5.5 | Human | |
| S0B5107 | Rat Anti-Mouse CD326 Antibody (S-R627) | Rat, S-R627 | Unconjugated | Mouse | |
| S0B5093 | FITC Rat Anti-Mouse CD326 Antibody (S-R627) | Rat, S-R627 | FITC | Mouse |
Four formats cover two species and two readouts. Human samples can be run in a single-color FITC tube or placed in a denser panel with PerCP-Cy5.5. Mouse models can be screened with the unconjugated reagent and confirmed with the directly labeled version. Keeping species and clone constant across a study is the simplest way to keep epithelial gate boundaries stable.
Reporting EpCAM Results Without Overclaiming
An EpCAM-positive event is not automatically a tumor cell. Normal epithelial cells can enter circulation after surgery or biopsy, and some leukocyte subsets bind reagents through Fc receptors. Report the CD45-negative, viability-dye-negative parent population explicitly. State the clone, the fluorophore and the dissociation method, since all three shift the measured frequency. Where EpCAM is used as a capture marker rather than a phenotyping marker, describe the enrichment step as well, because recovery and purity are different numbers.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.